Drug copies ready to take next bite out of Roche's cancer sales

LONDON (Reuters) - European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars. South Korea’s Celltrion is the biggest winner in the biosimilars boom, having tripled in value to $34 billion in the past year as it gears up for more produc...